1. patients with critical covid-19 and moderate covid-19 with other complication. 2. patients having thyroid dysfunction, pregnant or lactating mother. 3. it should not be used prior to or after radioiodine scintigraphy or radioiodine treatment of thyroid carcinoma. 4. patients allergic to iodine should be avoided 5. have participated in other clinical study 6. subjects with other severe acute or chronic conditions that may increase the risk of participation in the study and study treatment, or may interfere with interpretation of study results, and judged by the investigator as not suitable for participation in this clinical trial. b. healthy individual inclusion criteria: 1. healthy individual (non covid-19) 2. age -18 years and above (as below18 years lesser concentration of drug may be required). 3. consent of the participants who wish to participate.

1. patients with critical covid-19 and moderate covid-19 with other complication. 2. patients having thyroid dysfunction, pregnant or lactating mother. 3. it should not be used prior to or after radioiodine scintigraphy or radioiodine treatment of thyroid carcinoma. 4. patients allergic to iodine should be avoided 5. have participated in other clinical study 6. subjects with other severe acute or chronic conditions that may increase the risk of participation in the study and study treatment, or may interfere with interpretation of study results, and judged by the investigator as not suitable for participation in this clinical trial. b. healthy individual inclusion criteria: 1. healthy individual (non covid-19) 2. age -18 years and above (as below18 years lesser concentration of drug may be required). 3. consent of the participants who wish to participate.

patients with critical covid-19 and moderate covid-19 with other complication. patients having thyroid dysfunction, pregnant or lactating mother. it should not be used prior to or after radioiodine scintigraphy or radioiodine treatment of thyroid carcinoma. patients allergic to iodine should be avoided have participated in other clinical study subjects with other severe acute or chronic conditions that may increase the risk of participation in the study and study treatment, or may interfere with interpretation of study results, and judged by the investigator as not suitable for participation in this clinical trial. b. healthy individual inclusion criteria: healthy individual (non covid-19) age -18 years and above (as below18 years lesser concentration of drug may be required). consent of the participants who wish to participate.

patients with critical covid-19 and moderate covid-19 with other complication. patients having thyroid dysfunction, pregnant or lactating mother. it should not be used prior to or after radioiodine scintigraphy or radioiodine treatment of thyroid carcinoma. patients allergic to iodine should be avoided have participated in other clinical study subjects with other severe acute or chronic conditions that may increase the risk of participation in the study and study treatment, or may interfere with interpretation of study results, and judged by the investigator as not suitable for participation in this clinical trial. b. healthy individual inclusion criteria: healthy individual (non covid-19) age -18 years and above (as below18 years lesser concentration of drug may be required). consent of the participants who wish to participate.

1. patients with critical covid-19 and moderate covid-19 with other complication. 2. patients having thyroid dysfunction, pregnant or lactating mother. 3. it should not be used prior to or after radioiodine scintigraphy or radioiodine treatment of thyroid carcinoma. 4. patients allergic to iodine should be avoided 5. have participated in other clinical study 6. subjects with other severe acute or chronic conditions that may increase the risk of participation in the study and study treatment, or may interfere with interpretation of study results, and judged by the investigator as not suitable for participation in this clinical trial. b. healthy individual inclusion criteria: 1. healthy individual (non covid-19) 2. age -18 years and above (as below18 years lesser concentration of drug may be required). 3. consent of the participants who wish to participate.

1. patients with critical covid-19 and moderate covid-19 with other complication. 2. patients having thyroid dysfunction, pregnant or lactating mother. 3. it should not be used prior to or after radioiodine scintigraphy or radioiodine treatment of thyroid carcinoma. 4. patients allergic to iodine should be avoided 5. have participated in other clinical study 6. subjects with other severe acute or chronic conditions that may increase the risk of participation in the study and study treatment, or may interfere with interpretation of study results, and judged by the investigator as not suitable for participation in this clinical trial. b. healthy individual inclusion criteria: 1. healthy individual (non covid-19) 2. age -18 years and above (as below18 years lesser concentration of drug may be required). 3. consent of the participants who wish to participate.